IDH2
IDH2 is a mitochondrial enzyme essential for the TCA cycle and NADPH production. Mutations in IDH2 are primary drivers of acute myeloid leukemia (AML) and angioimmunoblastic T-cell lymphoma, causing the production of the toxic oncometabolite 2-hydroxyglutarate.
Key Takeaways
- •IDH2 is the mitochondrial version of IDH1, producing energy and signals inside the "power plant."
- •Mutations (e.g., R140Q) convert the enzyme into a factory for the toxic oncometabolite 2-HG.
- •IDH2-mutant 2-HG is more common in leukemia than in brain tumors.
- •Enasidenib is a targeted inhibitor that blocks the mutant IDH2 engine to treat AML.
Basic Information
- Gene Symbol
- IDH2
- Full Name
- Isocitrate Dehydrogenase (NADP(+)) 2
- Also Known As
- D2HGDonlyIDHIDPIDPMmIDH2PICD
- Location
- 15q26.1
- Protein Type
- Mitochondrial Metabolic Enzyme
- Protein Family
- Isocitrate dehydrogenase family
Related Isoforms
Key SNPs
The most common IDH2 mutation in AML; causes a neo-morphic production of 2-HG and is highly sensitive to the targeted inhibitor Enasidenib.
A pathogenic mutation associated with significantly higher levels of 2-HG production compared to the R140 variant; found in both AML and gliomas.
Common marker used in GWAS panels to identify the IDH2 locus and its association with metabolic and cardiovascular traits.
Overview
IDH2 (Isocitrate Dehydrogenase 2) encodes an enzyme that is the mitochondrial counterpart to IDH1. It catalyzes the same fundamental reaction—the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG)—but it does so within the mitochondrial matrix. This makes IDH2 a critical component of the Tricarboxylic Acid (TCA) cycle, the central energy-producing hub of the cell, and a vital source of mitochondrial NADPH required for managing local oxidative stress.
The clinical significance of IDH2 is defined by its role as a "metabolic oncogene." Like its cytoplasmic sibling IDH1, certain point mutations in IDH2 endow the enzyme with a gain-of-function ability to produce 2-hydroxyglutarate (2-HG). This "oncometabolite" leaks out of the mitochondria and clogs the cell’s epigenetic machinery, preventing blood cells from maturing and leading to the development of acute myeloid leukemia (AML) and specific types of T-cell lymphoma.
Conceptual Model
A simplified mental model for the pathway:
IDH2 mutations turn the cell's energy center into a source of epigenetic toxin.
Core Health Impacts
- • Mitochondrial Redox: Provides the NADPH required for the local antioxidant defense within the power plant
- • TCA Cycle Flux: Maintains the flow of carbon skeletons through the central metabolic hub of the cell
- • Epigenetic Remodeling: Regulates the levels of alpha-ketoglutarate needed for global DNA and histone demethylation
- • Oncogenesis: Neo-morphic mutations are primary drivers of AML and certain peripheral T-cell lymphomas
- • Hypoxia Response: Influences the stability of HIF-1α by providing the cofactor needed for its degradation
Protein Domains
Mitochondrial Targeting
An N-terminal leader sequence that directs the protein from the cytoplasm into the mitochondrial matrix.
NADP+ Binding Pocket
A structural fold that holds the coenzyme required to capture energy during the conversion of isocitrate.
R140 / R172 Sites
Critical arginine residues in the active site; mutations here fundamentally re-program the enzyme's chemical output.
Upstream Regulators
Isocitrate Activator
The primary substrate provided by the early steps of the TCA cycle.
NADP+ Activator
The essential co-factor; its availability in the mitochondria dictates the speed of the IDH2 engine.
Citrate Activator
Metabolic precursor that can be converted into isocitrate to fuel the mitochondrial pathway.
HIF-1α Modulator
Can modulate IDH2 expression to help the cell adapt its mitochondrial metabolism to low oxygen.
Oncogenic Mutations Modulator
Structural changes like R140Q that create a new chemical active site for 2-HG production.
Downstream Targets
alpha-Ketoglutarate (α-KG) Activates
The healthy product; required for the TCA cycle and over 60 diverse cellular enzymes.
NADPH Activates
The reducing agent needed to keep mitochondrial glutathione in its protective active state.
2-Hydroxyglutarate (2-HG) Activates
The toxic product of mutant IDH2; it competes with α-KG to sabotage cellular machinery.
TET2 (Inhibition) Inhibits
Mutant-derived 2-HG inhibits this master DNA-cleaner, leading to hyper-methylation.
KDM (Inhibition) Inhibits
Inhibits histone demethylases, locking the cell's chromatin in an "immature" and oncogenic state.
Role in Aging
IDH2 is a cornerstone of "mitochondrial and epigenetic aging." As we age, the efficiency of the IDH2 engine in our power plants naturally declines, contributing to the bioenergetic failure and loss of genomic precision that characterize the biological aging process.
Bioenergetic Decay
Age-related loss of IDH2 activity reduces the "fuel" (NADPH) available to protect mitochondria from free radical damage.
Epigenetic Thinning
Declining mitochondrial α-KG levels in late life can lead to a global loss of the epigenetic marks that define cell identity.
Clonal Hematopoiesis
Somatic IDH2 mutations in aging bone marrow create mutant clones that are often precursors to leukemia.
Mitophagy Failure
Dysregulated IDH2 signaling can impair the quality-control signals needed to clear damaged mitochondria in aging cells.
Vascular Metabolism
Loss of IDH2 function in the heart and blood vessels contributes to the metabolic stiffening of the cardiovascular system.
Longevity Synergy
Favorable IDH2 variants that support robust mitochondrial function are being studied for their role in extending healthy lifespan.
Disorders & Diseases
Acute Myeloid Leukemia (AML)
IDH2 mutations (especially R140Q) occur in ~15% of AML cases. It drives a "differentiation block" that keeps blood cells from maturing.
D-2-Hydroxyglutaric Aciduria
A rare metabolic disorder caused by germline IDH2 mutations, leading to massive systemic 2-HG levels and neurodegeneration.
Angioimmunoblastic T-cell Lymphoma
A specific type of lymphoma frequently characterized by IDH2 R172 mutations, which reprogram the immune cell identity.
Cholangiocarcinoma
Bile duct cancers can be driven by IDH2 mutations, creating a unique molecular subtype with specific therapeutic needs.
Glioma (Secondary)
While less common than IDH1, IDH2 mutations are found in a subset of brain tumors, leading to the same 2-HG-driven pathology.
The Mitochondrial Sink
IDH2 taught us that the mitochondria act as a "sink" for metabolic signals. When the sink is broken (by a mutation), it doesn't just affect energy; it floods the entire cell with a toxic soot (2-HG) that changes the way the DNA is read.
Interventions
Supplements
The mandatory cofactor for the TET2 enzyme; high-dose Vitamin C may help overcome the 2-HG block in mutant cells.
Supplementation with the healthy product of IDH2 is being researched for its potential to support mitochondrial resilience.
The precursor to the NADP+ that the IDH2 enzyme requires to function as a mitochondrial shield.
Supports the overall health of the mitochondrial matrix where IDH2 performs its primary catalytic duties.
Lifestyle
Endurance training increases mitochondrial biogenesis and enhances the total capacity of the IDH2 engine.
Triggers metabolic shifts that favor the efficient use of the TCA cycle and mitochondrial repair pathways.
Ensures the availability of the sulfur-containing amino acids needed for the mitochondrial glutathione system.
Minimizing exposure to pesticides and heavy metals protects the delicate matrix where IDH2 operates.
Medicines
A targeted small molecule that specifically inhibits the mutant IDH2 protein, restoring normal blood cell maturation in AML.
Used in IDH-mutant cancers to "un-do" the DNA hypermethylation caused by the oncometabolite 2-HG.
Being studied for their synergy with IDH2 inhibitors, as mutant cells have weakened DNA repair capabilities.
May help the cell clear out the metabolic stress and damaged mitochondria resulting from IDH2 failure.
Lab Tests & Biomarkers
Oncology Diagnostics
Standard clinical sequencing for AML patients to determine eligibility for Enasidenib therapy.
A blood biomarker used to track the "metabolic soot" level and the effectiveness of IDH2-targeted treatment.
Genetic Screening
Assesses both family members to identify the molecular driver of a patient's leukemia or brain tumor.
Detects the early somatic IDH2 mutations in the blood that signal an increased risk for future leukemia.
Mitochondrial Assays
Research marker used to assess the flux through the first steps of the mitochondrial TCA cycle.
An indirect measure of the "health and density" of the organelles that IDH2 maintains.
Hormonal Interactions
Thyroid Hormone (T3) Primary Regulator
The master upregulator of mitochondrial enzymes; it sets the baseline speed of the IDH2 engine.
Cortisol Modulator
Stress hormones can acutely shift mitochondrial priorities, potentially altering the load on the IDH2 pathway.
Insulin Regulator
Drives the glucose-to-citrate flux that provides the fuel for mitochondrial IDH2 activity.
Growth Hormone Synergist
Supports the biogenesis of new mitochondria and the maintenance of their internal enzymatic machinery.
Deep Dive
Network Diagrams
IDH2 and the Mitochondrial Soot
The Mitochondrial Engine: IDH2 and the Matrix
To understand IDH2, one must go inside the mitochondria—the power plant of the cell. While its sibling IDH1 works in the cell body, IDH2 is the master of the mitochondrial matrix.
The Clean Fuel: In a healthy cell, IDH2 is an essential part of the TCA cycle (the engine of energy). It takes isocitrate and turns it into:
- alpha-Ketoglutarate (α-KG): The primary signal that tells the cell everything is running smoothly.
- NADPH: The specific “reducing energy” needed to protect the power plant itself from being burned by its own heat (oxidative stress).
Local Protection: Because the mitochondria are the most oxidative part of the cell, the NADPH produced by IDH2 is the definitively important shield that prevents the organelle from accumulating the damage that we call “mitochondrial aging.”
The “Soot” Mutation: 2-HG and AML
The most important clinical fact about IDH2 is how it breaks in Acute Myeloid Leukemia (AML).
The R140 and R172 Mutations: These mutations happen at the core of the enzyme. They don’t just stop the engine; they change its chemistry (neo-morphic activity).
- The Soot Factory: Instead of making the clean α-KG signal, the mutant enzyme begins to produce a “metabolic soot” called 2-hydroxyglutarate (2-HG).
- ** Epigenetic clogging:** This 2-HG soot is incredibly sticky. It leaves the mitochondria and travels to the cell nucleus, where it “clogs” the enzymes (TET2) that are supposed to keep the DNA clean.
The Differentiation Block: Breaking the Cell’s Maturity
The result of the 2-HG soot is a differentiation block.
Immature Clones: In the bone marrow, blood cells are born as stem cells and must “mature” into red cells or white cells. The 2-HG from mutant IDH2 “locks” the epigenetic switches needed for maturation. The cells stay in a primitive, immortal, and rapidly dividing state. This is how a metabolic mistake becomes a life-threatening cancer.
The Precision Antidote: Because this cancer is “addicted” to the 2-HG soot, scientists have developed a drug—Enasidenib (Idhifa)—that specifically “plugs” the mutant IDH2 engine. By stopping the soot production, the drug allows the blood cells to “un-clog” their DNA and suddenly finish their maturation process. This revolutionary therapy has proven that we can treat cancer not by killing the cells with poison, but by restoring the healthy metabolic signal of the IDH2 gene.
Practical Note: The Power Plant Shield
IDH2 is your mitochondrial guard. Think of IDH2 as the person who checks the "air filters" inside your cell's power plants. It produces the NADPH that keeps those plants from rusting (oxidative stress). If your IDH2 is weak, your power plants age faster. Maintaining a metabolism that supports mitochondrial health—like exercise and healthy fats—is a requirement for supporting your IDH2 system.
Leukemia Awareness. Unlike IDH1, which is the "brain tumor" gene, IDH2 is primarily the "leukemia gene." If you have a family history of AML, knowing your somatic IDH2 status through a simple blood check (CHIP screening) can provide an early warning signal years before any clinical disease emerges.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first identified IDH2 mutations as a frequent and clinically significant event in leukemia.
The pivotal trial for Enasidenib, proving that metabolic inhibition of IDH2 can reverse the differentiation block in blood cancer.
First recognized the existence of a germline IDH2 mutation that leads to systemic oncometabolite toxicity.
Provided the first high-resolution structural look at how IDH2 coordinates its metal ions and substrates within the mitochondria.
Discovered that IDH2 mutations are specifically enriched in AITL, linking mitochondrial metabolism to immune cell cancer.